Cost Analysis of Dropless Cataract Surgery Prophylaxis with Intracameral Antibiotics and Subconjunctival Steroids.


Journal

Journal of cataract and refractive surgery
ISSN: 1873-4502
Titre abrégé: J Cataract Refract Surg
Pays: United States
ID NLM: 8604171

Informations de publication

Date de publication:
16 Jul 2024
Historique:
received: 22 02 2024
accepted: 10 07 2024
medline: 19 7 2024
pubmed: 19 7 2024
entrez: 18 7 2024
Statut: aheadofprint

Résumé

To determine whether dropless, injection-based cataract surgery prophylaxis with intracameral antibiotic and subconjunctival steroid may reduce healthcare system costs and patient out-of-pocket costs compared to topical medication regimens. United States national medical expenditures database. Retrospective cost analysis. Costs were analyzed for topical ophthalmics from the 2020 Medical Expenditure Panel Survey (MEPS) and for dropless medications from pharmaceutical invoices/catalogs. Main outcomes included system costs, from insurance and patient payments, and out-of-pocket costs for cataract surgery topical and dropless, injection-based prophylactic medication regimens, per eye and nationally. System costs for individual topical medications and same-class dropless, injection-based medications were compared using two-sided, one-sample t-tests. There were 583 prophylactic topical ophthalmic purchases in MEPS. Mean system costs per eye were $76.20 ± SD 39.07 for the lowest cost topical steroid (prednisolone) compared to $4.01 for the lowest cost subconjunctival steroid (triamcinolone acetonide) (p < 0.001). Per eye, the lowest cost dropless, injection-based regimen, at $15.91, results in an $87.99 (84.7%) reduction in overall healthcare costs and a $43.64 (100%) reduction in patient out-of-pocket costs relative to the lowest cost topical regimen ($103.90 ± 43.14 mean system cost and $43.64 ± 37.32 mean out-of-pocket cost per eye). Use of intracameral moxifloxacin and subconjunctival triamcinolone acetonide can reduce annual national healthcare system and out-of-pocket costs up to $450,000,000 and $225,000,000, respectively. An evidence-based cataract surgery prophylactic medication regimen of intracameral moxifloxacin and subconjunctival triamcinolone acetonide can reduce healthcare system and patient out-of-pocket costs in comparison to various topical regimens.

Identifiants

pubmed: 39025664
doi: 10.1097/j.jcrs.0000000000001526
pii: 02158034-990000000-00466
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Published by Wolters Kluwer on behalf of ASCRS and ESCRS.

Auteurs

Scott Massa (S)

Department of Ophthalmology, New York University Grossman School of Medicine, New York, NY.

David J Smits (DJ)

Cheyenne Eye Clinic and Surgery Center, Cheyenne, WY.

Alexander T Nguyen (AT)

Department of Ophthalmology, Yale New Haven Health, New Haven, CT.
The Eye Care Group, Waterbury, CT.

Sachi A Patil (SA)

Department of Ophthalmology, New York University Grossman School of Medicine, New York, NY.

Evan M Chen (EM)

Department of Ophthalmology, University of California, San Francisco School of Medicine, San Francisco, CA.

Scott Friedman (S)

Florida Retina Consultants, Lakeland, FL.

Ravi Parikh (R)

Department of Ophthalmology, New York University Grossman School of Medicine, New York, NY.
Manhattan Retina and Eye Consultants, New York, NY.

Classifications MeSH